Enanta Pharmaceuticals, Inc. announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at the 9th European Scientific Working Group on Influenza Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.
